LPTX vs. RVPH, ANEB, AFMD, TPST, LFVN, SLS, HOOK, VTVT, JAGX, and CRVS
Should you be buying Leap Therapeutics stock or one of its competitors? The main competitors of Leap Therapeutics include Reviva Pharmaceuticals (RVPH), Anebulo Pharmaceuticals (ANEB), Affimed (AFMD), Tempest Therapeutics (TPST), LifeVantage (LFVN), SELLAS Life Sciences Group (SLS), Hookipa Pharma (HOOK), vTv Therapeutics (VTVT), Jaguar Health (JAGX), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical preparations" industry.
Reviva Pharmaceuticals (NASDAQ:RVPH) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, community ranking, media sentiment, profitability, risk, institutional ownership and analyst recommendations.
In the previous week, Leap Therapeutics had 1 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 9 mentions for Leap Therapeutics and 8 mentions for Reviva Pharmaceuticals. Reviva Pharmaceuticals' average media sentiment score of 0.77 beat Leap Therapeutics' score of 0.35 indicating that Leap Therapeutics is being referred to more favorably in the news media.
Reviva Pharmaceuticals currently has a consensus target price of $16.33, indicating a potential upside of 860.78%. Leap Therapeutics has a consensus target price of $11.00, indicating a potential upside of 300.00%. Given Leap Therapeutics' higher probable upside, equities research analysts plainly believe Reviva Pharmaceuticals is more favorable than Leap Therapeutics.
Leap Therapeutics received 274 more outperform votes than Reviva Pharmaceuticals when rated by MarketBeat users. However, 88.89% of users gave Reviva Pharmaceuticals an outperform vote while only 68.72% of users gave Leap Therapeutics an outperform vote.
Reviva Pharmaceuticals has higher earnings, but lower revenue than Leap Therapeutics. Leap Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are held by institutional investors. 31.8% of Reviva Pharmaceuticals shares are held by insiders. Comparatively, 11.3% of Leap Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Reviva Pharmaceuticals' return on equity of -74.06% beat Leap Therapeutics' return on equity.
Reviva Pharmaceuticals has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.
Summary
Reviva Pharmaceuticals and Leap Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Leap Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Leap Therapeutics Competitors List
Related Companies and Tools
